GlassScriptPhysician profile
Dong H Lee
NPI 1134109200
$7,439.45
in general payments reported to CMS, 2019-2025
33 companies · $1,370 in 2025
The $1,370 reported for 2025 was more than what 92% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $854 · 2021: $1,623 · 2022: $1,226 · 2023: $1,082 · 2024: $433 · 2025: $1,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,564 · Travel and Lodging: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.49 |
| Travel and Lodging | $320.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,321.18 | 2019-2024 | |
| Amarin Pharma, INC. | $1,310.27 | 2019-2023 | |
| Amgen INC. | $1,032.57 | 2020-2025 | Repatha, Otezla, Prolia |
| Penumbra, INC. | $541.74 | 2025 | Indigo System |
| Lilly USA, LLC | $481.70 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $359.87 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.35 | 2021-2025 | Jardiance |
| Scilex Pharmaceuticals INC. | $269.67 | 2020-2024 | Ztlido |
| Inspiremd LTD | $232.98 | 2025 | Cguard Prime Carotid Stent System |
| Aimmune Therapeutics, INC. | $227.04 | 2024-2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $184.81 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $152.35 | 2020-2023 | Linzess |
| Gilead Sciences, INC. | $125.00 | 2023 | Vemlidy |
| Pfizer INC. | $109.33 | 2019-2023 | |
| Redhill Biopharma INC. | $109.03 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $97.68 | 2022-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $78.64 | 2023 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $73.22 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $58.47 | 2022 | |
| Merck Sharp & Dohme LLC | $52.79 | 2019-2021 | |
| Esperion Therapeutics, INC. | $39.22 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $38.98 | 2023 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.36 | 2022 | |
| Sumitomo Pharma America, INC. | $25.43 | 2023 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $23.27 | 2022 | |
| Edwards Lifesciences Corporation | $22.16 | 2021 | |
| Vivus LLC | $22.13 | 2022 | |
| Dexcom, INC. | $21.81 | 2023 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $21.76 | 2024 | Ibsrela |
| Arbor Pharmaceuticals, INC. | $19.57 | 2022 | |
| Astellas Pharma US INC | $17.99 | 2019 | |
| Ibsa Pharma INC. | $17.89 | 2023 | Tirosint, Licart |
| Horizon Therapeutics Plc | $15.19 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dong Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.